Patents by Inventor Paul Patrick Cleary

Paul Patrick Cleary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9127050
    Abstract: A number of ?-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by ?-hemolytic streptococci.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: September 8, 2015
    Assignees: Regents of the University of Minnesota, Wyeth LLC
    Inventors: Ingrid Lea Scully, Annaliesa Sybil Anderson, Michael Hagen, Stephen Bruce Olmsted, Paul Patrick Cleary
  • Publication number: 20140037669
    Abstract: A number of ?-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by ?-hemolytic streptococci.
    Type: Application
    Filed: July 16, 2013
    Publication date: February 6, 2014
    Inventors: Ingrid Lea Scully, Annaliesa Sybil Anderson, Michael Hagen, Stephen Bruce Olmsted, Paul Patrick Cleary
  • Patent number: 8440205
    Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: May 14, 2013
    Assignee: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Patent number: 7635483
    Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: December 22, 2009
    Assignee: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Patent number: 7256265
    Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: August 14, 2007
    Assignee: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Patent number: 6951653
    Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: October 4, 2005
    Assignee: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Publication number: 20040062777
    Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Application
    Filed: May 30, 2001
    Publication date: April 1, 2004
    Applicant: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Publication number: 20040052801
    Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Application
    Filed: April 11, 2003
    Publication date: March 18, 2004
    Applicant: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Publication number: 20020142009
    Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Application
    Filed: May 30, 2001
    Publication date: October 3, 2002
    Applicant: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Patent number: 6355255
    Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: March 12, 2002
    Assignee: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Patent number: 6270775
    Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: August 7, 2001
    Assignee: Regents of the University of Minnesota
    Inventor: Paul Patrick Cleary
  • Patent number: 5846547
    Abstract: Novel vaccines for use against .beta.-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against .beta.-hemolytic Streptococcus colonization or infection by administering such a vaccine.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: December 8, 1998
    Assignee: Regents of the University of Minnesota
    Inventor: Paul Patrick Cleary